1,036
Views
60
CrossRef citations to date
0
Altmetric
Reviews

Emerging roles for triggering receptor expressed on myeloid cells receptor family signaling in inflammatory diseases

&

References

  • Klesney-Tait J, Colonna M. Uncovering the TREM-1-TLR connection. Am. J. Physiol. Lung Cell. Mol. Physiol. 293(6), L1374–L1376 (2007).
  • Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease. Curr. Opin. Immunol. 21(1), 38–46 (2009).
  • Takaki R, Watson SR, Lanier LL. DAP12: an adapter protein with dual functionality. Immunol. Rev. 214, 118–129 (2006).
  • Clark GJ, Ju X, Tate C, Hart DN. The CD300 family of molecules are evolutionarily significant regulators of leukocyte functions. Trends Immunol. 30(5), 209–217 (2009).
  • Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 391(6668), 703–707 (1998).
  • Tomasello E, Desmoulins PO, Chemin K, Guia S, Cremer H, Ortaldo J et al. Combined natural killer cell and dendritic cell functional deficiency in KARAP/DAP12 loss-of-function mutant mice. Immunity 13(3), 355–364 (2000).
  • Tomasello E, Vivier E. KARAP/DAP12/TYROBP: three names and a multiplicity of biological functions. Eur. J. Immunol. 35(6), 1670–1677 (2005).
  • Bouchon A, Dietrich J, Colonna M. Cutting edge: Inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J. Immunol. 164(10), 4991–4995 (2000).
  • Allcock RJ, Barrow AD, Forbes S, Beck S, Trowsdale J. The human TREM gene cluster at 6p21.1 encodes both activating and inhibitory single IgV domain receptors and includes NKp44. Eur. J. Immunol. 33(2), 567–577 (2003).
  • Molloy EJ. Triggering receptor expressed on myeloid cells (TREM) family and the application of its antagonists. Recent Pat. Antiinfect. Drug Discov. 4(1), 51–56 (2009).
  • Sharif O, Knapp S. From expression to signaling: Roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology 213(9–10), 701–713 (2008).
  • Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410(6832), 1103–1107 (2001).
  • Gibot S, Kolopp-Sarda MN, Bene MC et al. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J. Exp. Med. 200(11), 1419–1426 (2004).
  • Gibot S, Massin F, Marcou M et al. TREM-1 promotes survival during septic shock in mice. Eur. J. Immunol. 37(2), 456–466 (2007).
  • Molad Y, Pokroy-Shapira E, Carmon V. CpG-oligodeoxynucleotide-induced TLR9 activation regulates macrophage TREM-1 expression and shedding. Innate Immun. 19(6), 623–630 (2013).
  • Netea MG, Azam T, Ferwerda G, Girardin SE, Kim SH, Dinarello CA. Triggering receptor expressed on myeloid cells-1 (TREM-1) amplifies the signals induced by the NACHT-LRR (NLR) pattern recognition receptors. J. Leukoc. Biol. 80(6), 1454–1461 (2006).
  • Dower K, Ellis DK, Saraf K, Jelinsky SA, Lin LL. Innate immune responses to TREM-1 activation: overlap, divergence, and positive and negative cross-talk with bacterial lipopolysaccharide. J. Immunol. 180(5), 3520–3534 (2008).
  • Watarai H, Sekine E, Inoue S, Nakagawa R, Kaisho T, Taniguchi M. PDC-TREM, a plasmacytoid dendritic cell-specific receptor, is responsible for augmented production of type I interferon. Proc. Natl Acad. Sci. USA 105(8), 2993–2998 (2008).
  • Wong-Baeza I, Gonzalez-Roldan N, Ferat-Osorio E et al. Triggering receptor expressed on myeloid cells (TREM-1) is regulated post-transcriptionally and its ligand is present in the sera of some septic patients. Clin. Exp. Immunol. 145(3), 448–455 (2006).
  • Haselmayer P, Grosse-Hovest L, von Landenberg P, Schild H, Radsak MP. TREM-1 ligand expression on platelets enhances neutrophil activation. Blood 110(3), 1029–1035 (2007).
  • Gomez-Pina V, Soares-Schanoski A, Rodriguez-Rojas A et al. Metalloproteinases shed TREM-1 ectodomain from lipopolysaccharide-stimulated human monocytes. J. Immunol. 179(6), 4065–4073 (2007).
  • Dimopoulou I, Pelekanou A, Mavrou I et al. Early serum levels of soluble triggering receptor expressed on myeloid cells-1 in septic patients: correlation with monocyte gene expression. J. Crit. Care 27(3), 294–300 (2012).
  • Bopp C, Bierhaus A, Hofer S et al. Bench-to-bedside review: the inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit. Care 12(1), 201 (2008).
  • El Mezayen R, El Gazzar M, Seeds MC, McCall CE, Dreskin SC, Nicolls MR. Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin. Immunol. Lett. 111(1), 36–44 (2007).
  • Wu J, Li J, Salcedo R, Mivechi NF, Trinchieri G, Horuzsko A. The proinflammatory myeloid cell receptor TREM-1 controls kupffer cell activation and development of hepatocellular carcinoma. Cancer Res. 72(16), 3977–3986 (2012).
  • Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N. Engl. J. Med. 350(5), 451–458 (2004).
  • Yasuda T, Takeyama Y, Ueda T et al. Increased levels of soluble triggering receptor expressed on myeloid cells-1 in patients with acute pancreatitis. Crit. Care Med. 36(7), 2048–2053 (2008).
  • Murakami Y, Akahoshi T, Aoki N, Toyomoto M, Miyasaka N, Kohsaka H. Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis. Arthritis Rheum. 60(6), 1615–1623 (2009).
  • Schenk M, Bouchon A, Seibold F, Mueller C. TREM-1--expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J. Clin. Invest. 117(10), 3097–3106 (2007).
  • Ho CC, Liao WY, Wang CY et al. TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am. J. Respir. Crit. Care Med. 177(7), 763–770 (2008).
  • Karapanagiotou EM, Pelekanou E, Charpidou A et al. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies. Anticancer Res. 28(2B), 1411–1415 (2008).
  • Turnbull IR, Gilfillan S, Cella M et al. Cutting edge: TREM-2 attenuates macrophage activation. J. Immunol. 177(6), 3520–3524 (2006).
  • Ito H, Hamerman JA. TREM-2, triggering receptor expressed on myeloid cell-2, negatively regulates TLR responses in dendritic cells. Eur. J. Immunol. 42(1), 176–185 (2012).
  • Daws MR, Sullam PM, Niemi EC, Chen TT, Tchao NK, Seaman WE. Pattern recognition by TREM-2: binding of anionic ligands. J. Immunol. 171(2), 594–599 (2003).
  • N’Diaye EN, Branda CS, Branda SS et al. TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria. J. Cell Biol. 184(2), 215–223 (2009).
  • Chen Q, Zhang K, Jin Y et al. Triggering receptor expressed on myeloid cells-2 protects against polymicrobial sepsis by enhancing bacterial clearance. Am. J. Respir. Crit. Care Med. 188(2), 201–212 (2013).
  • Washington AV, Schubert RL, Quigley L et al. A TREM family member, TLT-1, is found exclusively in the alpha-granules of megakaryocytes and platelets. Blood 104(4), 1042–1047 (2004).
  • Barrow AD, Astoul E, Floto A et al. Cutting edge: TREM-like transcript-1, a platelet immunoreceptor tyrosine-based inhibition motif encoding costimulatory immunoreceptor that enhances, rather than inhibits, calcium signaling via SHP-2. J. Immunol. 172(10), 5838–5842 (2004).
  • Washington AV, Gibot S, Acevedo I et al. TREM-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humans. J. Clin. Invest. 119(6), 1489–1501 (2009).
  • Derive M, Bouazza Y, Sennoun N et al. Soluble TREM-like transcript-1 regulates leukocyte activation and controls microbial sepsis. J. Immunol. 188(11), 5585–5592 (2012).
  • Paloneva J, Manninen T, Christman G et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am. J. Hum. Genet. 71(3), 656–662 (2002).
  • Tanaka J. Leukoencephalopathic alteration in membranous lipodystrophy. Acta Neuropathol. 50(3), 193–197 (1980).
  • Kalimo H, Sourander P, Jarvi O, Hakola P. Vascular changes and blood-brain barrier damage in the pathogenesis of polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (membranous lipodystrophy). Acta Neurol. Scand. 89(5), 353–361 (1994).
  • Bird TD, Koerker RM, Leaird BJ, Vlcek BW, Thorning DR. Lipomembranous polycystic osteodysplasia (brain, bone, and fat disease): a genetic cause of presenile dementia. Neurology 33(1), 81–86 (1983).
  • Paloneva J, Kestila M, Wu J et al. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat. Genet. 25(3), 357–361 (2000).
  • Cella M, Buonsanti C, Strader C, Kondo T, Salmaggi A, Colonna M. Impaired differentiation of osteoclasts in TREM-2-deficient individuals. J. Exp. Med. 198(4), 645–651 (2003).
  • Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E et al. TREM2 variants in alzheimer’s disease. N. Engl. J. Med. 368(2), 117–127 (2013).
  • Piccio L, Buonsanti C, Mariani M et al. Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Eur. J. Immunol. 37(5), 1290–1301 (2007).
  • Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56(7), 1761–1772 (2007).
  • Davis JE, Gabler NK, Walker-Daniels J, Spurlock ME. Tlr-4 deficiency selectively protects against obesity induced by diets high in saturated fat. Obesity (Silver Spring) 16(6), 1248–1255 (2008).
  • Suganami T, Tanimoto-Koyama K, Nishida J et al. Role of the toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler. Thromb. Vasc. Biol. 27(1), 84–91 (2007).
  • Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J. Intern. Med. 245(6), 621–625 (1999).
  • Arts RJ, Joosten LA, Dinarello CA, Kullberg BJ, van der Meer JW, Netea MG. TREM-1 interaction with the LPS/TLR4 receptor complex. Eur. Cytokine Netw. 22(1), 11–14 (2011).
  • Fortin CF, Lesur O, Fulop T Jr. Effects of TREM-1 activation in human neutrophils: Activation of signaling pathways, recruitment into lipid rafts and association with TLR4. Int. Immunol. 19(1), 41–50 (2007).
  • Kim SJ, Choi Y, Choi YH, Park T. Obesity activates toll-like receptor-mediated proinflammatory signaling cascades in the adipose tissue of mice. J. Nutr. Biochem. 23(2), 113–122 (2012).
  • Kim EJ, Choi MR, Park H et al. Dietary fat increases solid tumor growth and metastasis of 4T1 murine mammary carcinoma cells and mortality in obesity-resistant BALB/c mice. Breast Cancer Res. 13(4), R78 (2011).
  • Gea-Sorli S, Bonjoch L, Closa D. Differences in the inflammatory response induced by acute pancreatitis in different white adipose tissue sites in the rat. PLoS ONE 7(8), e41933 (2012).
  • Dowal L, Yang W, Freeman MR, Steen H, Flaumenhaft R. Proteomic analysis of palmitoylated platelet proteins. Blood 118(13), e62–e73 (2011).
  • Cannon JP, O’Driscoll M, Litman GW. Specific lipid recognition is a general feature of CD300 and TREM molecules. Immunogenetics 64(1), 39–47 (2012).
  • Klesney-Tait J, Keck K, Li X et al. Transepithelial migration of neutrophils into the lung requires TREM-1. J. Clin. Invest. 123(1), 138–149 (2013).
  • Chen LC, Laskin JD, Gordon MK, Laskin DL. Regulation of TREM expression in hepatic macrophages and endothelial cells during acute endotoxemia. Exp. Mol. Pathol. 84(2), 145–155 (2008).
  • Rigo I, McMahon L, Dhawan P et al. Induction of triggering receptor expressed on myeloid cells (TREM-1) in airway epithelial cells by 1,25(OH)(2) vitamin D(3). Innate Immun. 18(2), 250–257 (2012).
  • del Fresno C, Gomez-Pina V, Lores V et al. Monocytes from cystic fibrosis patients are locked in an LPS tolerance state: Down-regulation of TREM-1 as putative underlying mechanism. PLoS ONE 3(7), e2667 (2008).
  • Boufenzer A, Sennoun N, Bouazza Y, Derive M, Bollaert P, Gibot S. Role of TREM-1 in endothelial dysfunction during experimental sepsis. Crit. Care 16( Suppl. 3), 49 (2012).
  • Gunnett CA, Lund DD, McDowell AK, Faraci FM, Heistad DD. Mechanisms of inducible nitric oxide synthase-mediated vascular dysfunction. Arterioscler. Thromb. Vasc. Biol. 25(8), 1617–1622 (2005).
  • Gibot S, Buonsanti C, Massin F et al. Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock. Infect. Immun. 74(5), 2823–2830 (2006).
  • Derive M, Boufenzer A, Bouazza Y et al. Effects of a TREM-like transcript 1-derived peptide during hypodynamic septic shock in pigs. Shock 39(2), 176–182 (2013).
  • Umemoto E, Tanaka T, Kanda H et al. Nepmucin, a novel HEV sialomucin, mediates L-selectin-dependent lymphocyte rolling and promotes lymphocyte adhesion under flow. J. Exp. Med. 203(6), 1603–1614 (2006).
  • Jin S, Umemoto E, Tanaka T et al. Nepmucin/CLM-9, an ig domain-containing sialomucin in vascular endothelial cells, promotes lymphocyte transendothelial migration in vitro. FEBS Lett. 582(20), 3018–3024 (2008).
  • Bhasin M, Huang Z, Pradhan-Nabzdyk L et al. Temporal network based analysis of cell specific vein graft transcriptome defines key pathways and hub genes in implantation injury. PLoS ONE 7(6), e39123 (2012).
  • Youssef RE, Ledingham MA, Bollapragada SS et al. The role of toll-like receptors (TLR-2 and −4) and triggering receptor expressed on myeloid cells 1 (TREM-1) in human term and preterm labor. Reprod. Sci. 16(9), 843–856 (2009).
  • de Souza AW, Westra J, Limburg PC, Bijl M, Kallenberg CG. HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis. Autoimmun. Rev. 11(12), 909–917 (2012).
  • Kanellakis P, Agrotis A, Kyaw TS et al. High-mobility group box protein 1 neutralization reduces development of diet-induced atherosclerosis in apolipoprotein e-deficient mice. Arterioscler. Thromb. Vasc. Biol. 31(2), 313–319 (2011).
  • Limana F, Germani A, Zacheo A et al. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ. Res. 97(8), e73–e83 (2005).
  • Kitahara T, Takeishi Y, Harada M et al. High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice. Cardiovasc. Res. 80(1), 40–46 (2008).
  • Kim F, Pham M, Luttrell I et al. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ. Res. 100(11), 1589–1596 (2007).
  • Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105(10), 1158–1161 (2002).
  • Michelsen KS, Wong MH, Shah PK et al. Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl Acad. Sci. USA 101(29), 10679–10684 (2004).
  • Gareus R, Kotsaki E, Xanthoulea S et al. Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis. Cell Metab. 8(5), 372–383 (2008).
  • Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 25(6), 1102–111 (2005).
  • Zhang X, Wang XG, Xie YQ et al. Role of triggering receptor expressed on myeloid cells-1 on coxsackievirus B3-induced inflammation and cardiomyocyte injury. Zhonghua Xin Xue Guan Bing Za Zhi 40(5), 411–415 (2012).
  • Schiechl G, Brunner SM, Kesselring R et al. Inhibition of innate co-receptor TREM-1 signaling reduces CD4(+) T cell activation and prolongs cardiac allograft survival. Am. J. Transplant. 13(5),1168–1180 (2013).
  • Hosoda H, Tamura H, Kida S, Nagaoka I. Transcriptional regulation of mouse TREM-1 gene in RAW264.7 macrophage-like cells. Life Sci. 89(3–4), 115–122 (2011).
  • Zeng H, Ornatowska M, Joo MS, Sadikot RT. TREM-1 expression in macrophages is regulated at transcriptional level by NF-kappaB and PU.1. Eur. J. Immunol. 37(8), 2300–2308 (2007).
  • Bosco MC, Pierobon D, Blengio F et al. Hypoxia modulates the gene expression profile of immunoregulatory receptors in human mature dendritic cells: Identification of TREM-1 as a novel hypoxic marker in vitro and in vivo. Blood 117(9), 2625–2639 (2011).
  • Murat A, Migliavacca E, Hussain SF et al. Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS ONE 4(6), e5947 (2009).
  • Paloneva J, Mandelin J, Kiialainen A et al. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J. Exp. Med. 198(4), 669–675 (2003).
  • Roumier A, Bechade C, Poncer JC et al. Impaired synaptic function in the microglial KARAP/DAP12-deficient mouse. J. Neurosci. 24(50), 11421–11428 (2004).
  • Kaifu T, Nakahara J, Inui M et al. Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J. Clin. Invest. 111(3), 323–332 (2003).
  • Hamerman JA, Tchao NK, Lowell CA, Lanier LL. Enhanced toll-like receptor responses in the absence of signaling adaptor DAP12. Nat. Immunol. 6(6), 579–586 (2005).
  • Turnbull IR, McDunn JE, Takai T, Townsend RR, Cobb JP, Colonna M. DAP12 (KARAP) amplifies inflammation and increases mortality from endotoxemia and septic peritonitis. J. Exp. Med. 202(3), 363–369 (2005).
  • Lucas M, Daniel L, Tomasello E et al. Massive inflammatory syndrome and lymphocytic immunodeficiency in KARAP/DAP12-transgenic mice. Eur. J. Immunol. 32(9), 2653–2663 (2002).
  • Seno H, Miyoshi H, Brown SL, Geske MJ, Colonna M, Stappenbeck TS. Efficient colonic mucosal wound repair requires Trem2 signaling. Proc. Natl Acad. Sci. USA 106(1), 256–261 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.